MEDTRONIC INTERSTIM SACRAL NERVE STIMULATION THERAPY SYSTEM
Medtronic Neuromodulation · Decision date Mar 14, 2011
What did the FDA approve?
FDA record P080025 shows a March 14, 2011 approval for the Medtronic InterStim Therapy System. The stated indication is treatment of chronic fecal incontinence in patients who have failed or could not tolerate more conservative treatments.
The record identifies the device as an implanted electrical device intended for treatment of fecal incontinence, with product code QON and applicant Medtronic Neuromodulation. The source does not state whether this action is an original PMA or a supplement, and it contains no safety or effectiveness data.
FDA approval order statement
APPROVAL FOR THE MEDTRONIC INTERSTIM THERAPY SYSTEM. THE DEVICE IS INDICATED FOR THE TREATMENT OF CHRONIC FECAL INCONTINENCE IN PATIENTS WHO HAVE FAILED OR COULD NOT TOLERATE MORE CONSERVATIVE TREATMENTS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Mar 14, 2011
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080025
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic Neuromodulation
- Product code
- QON
- Decision code
- APPR
- Decision date
- Mar 14, 2011
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implanted electrical device intended for treatment of fecal incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- QON
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P080025 received
Application receipt date recorded by FDA.
P080025 · FDA decision
APPR
P080025/S352 · Related supplement
InterStim Therapy System, Verify Evaluation System
P080025/S351 · Related supplement
lnterStim Therapy System, Verify Evaluation System
P080025/S353 · Related supplement
InterStim Therapy System, Verify Evaluation System
P080025/S354 · Related supplement
InterStim Therapy System, Verify Evaluation System (SNS Bowel Neurostimulator 97800), (SNS Bowel Neurostimulators Impl
Timeline entries are records held by MedtechLedger for P080025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 9, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Ms Rcw225, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P080025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


